Tenaya Therapeutics (TNYA) Leerink’s Global Healthcare Conference 2025 summary

Market and regulatory environment

• Genetic medicines face challenging market sentiment, with investors seeking more clinical data for confidence.

• Regulatory agencies are increasingly open to accelerated approvals for gene therapies based on early surrogate endpoints, as seen with Rocket Pharmaceuticals and Lexeo.

• Recent financing has provided over $100 million in cash, supporting key clinical milestones over the next 12-15 months.

Clinical pipeline progress and catalysts

• Active dosing is ongoing in TN-201 and TN-401 gene therapy studies, with significant data readouts expected in the next 12-18 months.

• TN-201 targets MYBPC3-related hypertrophic cardiomyopathy, with strong preclinical data and high patient and physician interest; full cohort data expected in the first half of next year.

• TN-401 addresses arrhythmogenic cardiomyopathy due to PKP2 mutations, focusing on early safety and biomarker data, with initial clinical data anticipated in the second half of this year.

• Both programs emphasize safety, cardiac transduction, RNA/protein expression, and disease-specific clinical endpoints.

Enrollment, patient interest, and data strategy

• Patient and physician interest in TN-201 is high, with robust enrollment in both clinical and natural history studies.

• Sentinel dosing protocols are being followed, and the company is on track to meet dosing and data milestones.

• More than 220 pediatric patients are enrolled in the natural history study for hypertrophic cardiomyopathy, and over 100 in the PKP2 study, supporting regulatory and clinical strategy.